Clinical Trial

Durvalumab With Consolidative Radiochemotherapy and Ablative Stereotactic Radiotherapy in Oligometastatic ES-SCLC

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
Open-label, single-arm, prospective multicenter phase II clinical trial to determine the efficacy of immunotherapy with durvalumab concomitant with radiochemotherapy, followed by durvalumab maintenance therapy in combination with stereotactic radiotherapy in extensive stage SCLC
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-01-16.
Trial Details
NCT Number NCT06223711
Lead Sponsor Universität des Saarlandes
Conditions Extensive-stage Small-cell Lung Cancer
Enrollment 43 participants
Start Date 2023-10-06
Primary Completion 2027-03 (estimated)
Study Completion 2027-12 (estimated)
Updated on ClinicalTrials.gov 2024-04-05